In January, we noted that the new U.S. Attorney in Massachusetts, Andrew Lelling, had publicly stated that he plans to keep the pressure on drug makers and patient assistance charities that are involved in “crooked” donations – see “Massachusetts’ New U.S. Attorney Vows to Continue Pressure on Drug Makers and Patient Assistance Programs.”
Lelling appears to be keeping to that promise based on a disclosure by Dublin-based drug maker Jazz Pharmaceuticals PLC (Jazz) in a recent quarterly Securities and Exchange Commission (SEC) filing. Jazz is the maker of Xyrem, an expensive drug used primarily in the treatment of narcolepsy.
Jazz, like many other pharmaceutical companies, engages in the practice of donating large sums to charitable Patient Assistance Programs that help patients, particularly those served by federally-funded health programs like Medicare and Medicaid, afford expensive prescription drugs by funding health insurance copayments. The programs rely on government protection from Kickback liability, which is generally granted so long as the programs demonstrate that a bona fide charitable organization is interposed between the drug manufacturers and the recipients of aid. Many pharmaceutical makers have run into trouble, however, when those donations begin to look more like kickbacks.
Jazz isn’t the first, and is unlikely to be the last, pharmaceutical company to run afoul of the DOJ regarding Patient Assistance Program donations. In the past year a number of companies have received similar subpoenas and/or reached significant financial settlements with the government, including United Therapeutics Corp., Valeant Pharmaceuticals, Gilead, and Biogen.